We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Novavax Inc | NASDAQ:NVAX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.41 | -8.32% | 4.52 | 4.52 | 4.63 | 5.045 | 4.725 | 4.93 | 4,846,191 | 00:59:41 |
From May 2019 to May 2024
Novavax Inc. shares fell 85% in after-hours trading Thursday after the vaccine company reported unfavorable results from two clinical trials.
A drug candidate known as the RSV F Vaccine didn't meet its efficacy goals, including the primary objective related to prevention of respiratory tract disease.
"We are both surprised and disappointed by the outcome" of the Resolve Phase 3 trial, the company said.
Shares recently traded at $1.29, compared with their 4 p.m. closing price of $8.34.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
September 15, 2016 17:45 ET (21:45 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Novavax Chart |
1 Month Novavax Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
